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Philip McTernan is a Reader Associate Professor within Warwick Medical School at the University of Warwick. His
main interests involve understanding the causes and underlying mechanisms of obesity mediated type 2 diabetes
and investigating potential therapeutic targets. He is currently researching the origins of inflammation in human
adipocytes and is the Section Editor for the new ‘Basic Science’ section in BMC Obesity. In this interview we find out
a little more about the key issues in this area of obesity research.How did you first become interested in
obesity research?
My earliest interaction with obesity-related research was
in university during my first undergraduate biochemistry
year, in the first ever lecture I attended at university.
During this lecture I was subjected to an overview of the
myriad of metabolic pathways I would need to learn and
the challenges ahead to secure my degree. I almost ran
from the lecture theatre there and then. Particularly as
we were informed we would have to learn all of these
human metabolism pathways in significant detail. This
was back in the late 1980’s before molecular biology had
taken hold in my world.
Looking back at this key personal event for me in the
lecture theatre, I considered the scale of the learning
task and all those eminent scientists that had brought to
coalesce this knowledge in front of me. I literally did
think, do I run for the hills or take it on? I chose the lat-
ter as you may have suspected, partly as the exit out of
my row was blocked either way, partly because my bio-
chemistry lecturer was a formidable character, and lastly
because maybe I could do it. Little did I realize then
how relatively simple the knowledge I was required to ab-
sorb, learn and regurgitate would be as the world of obes-
ity was set to explode with research in so many new areas.
However, during my undergraduate degree adipose tissue
was then viewed as a storage tissue and an apparently dull
one, and so attracted comparatively little interest from myCorrespondence: P.G.McTernan@warwick.ac.uk
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stated.then lecturers, in terms of comment or discussion. In fact,
the world of obesity only came into my line of fire during
my first postdoctoral research post. I remember being
asked in the interview a lot of technical questions on my
molecular and cell culture knowledge, whilst my questions
to the panel were more based around the actual project
on human adipose tissue. I soon realised why the panel
were keen on my technical skill; no one had much expert-
ise yet in culturing isolated human adipocytes as they are
tricky floating cells to keep happy. I relished the prospect
of the role however, as it gave me time to gain extensive
knowledge on working with human adipose tissue and iso-
lated adipocytes, and to study the effects of perturbing
these cells in different ways with a clinical lean.Could you tell us about the career path that led you
to your current position and research interests?
From my first postdoctoral research fellow post in the
mid 90’s I joined the field of obesity research, following
my doctorate on leukaemic therapies. I had appeared to
have left the mainstream cancer field to join the back
waters of adipose tissue metabolism. I even remember a
conference in Dublin, where Professor O’Rahilly gave a
lecture to what was then a relatively small crowd of
die-hard obesity researchers, in which he discussed his
apparent many long years in the back waters of obesity
research, with the concluding remarks that “the times
were a-changing”. Little did I realize then how right he
was and how fortunate I was to be working in the obesity
field with some under-valued yet bright scientists from
across the world. Perhaps due to my lack of knowledge. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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fellow in the field of obesity began to feel a bit like
working in the ‘Wild West’. To me it appeared like a
new frontier with endless possibilities for both what
could be done and how we could do it, as molecular
biology techniques began to provide quick new infor-
mation to somewhat overshadow the prior arduous and
time-consuming studies.
In the field of obesity the story of leptin appeared to
be a Pandora’s box of new possibilities. As a team we
began exploring what these human adipocytes could
produce, what would regulate adipokine production as
well as proliferation, and how therapeutics might influence
their metabolic functions. It was an exciting time as fat
cells seemed to be incredibly versatile cells without the
burden of decades of prior history as no one knew what
they did. Our research began examining whether the
adipokines noted in mice were expressed or relevant in
human adipose tissue, and how conditions such as obesity
and diabetes affected their regulation. Studies by the team
examined how insulin influenced, and agents such as
thiazolidinediones impacted adipokine function. The
research became more aligned to the clinical end with
a particular focus on this angle, prior to the economic and
funding pressures to do translational research becoming
apparent.
In terms of my current research, I continue to pursue
my interest into the role of inflammation and the impact
that metabolic state has on adipocyte cell function. I
also have a continuing interest in nutrition, especially
micronutrients and new health interventions concerning
these, working to understand their impact on reducing
inflammation and insulin resistance. Like most researchers,
I am also always interested in new developments in the
field of obesity and their implications on our current
studies.
What changes have you seen over the years in
how obesity research is conducted?
Science’s capability and our understanding of obesity - its
impact on health as well as our molecular understanding
of cellular mechanisms, seems to have increased at an
unprecedented exponential pace.
It was during the 90’s that these apparently ‘backwater’
obesity scientists were making heady new insights that
would change the landscape of obesity research forever.
In those early days the research was not always readily
translatable, yet key to our fundamental understanding
was the potential impact adipose tissue could have on
health. We live in a different world today, as obesity is a
readily identifiable global health problem for anyone to
see. Human obesity is posing significant financial challenges
to governments and health care providers, since the
majority of us, myself included, are getting fatter day byday. To me it seems even more imperative that we do
align the research to be translatable to human health. Yet
it is also clear that we also do still need research that may
not be readily translatable. We need new research ideas in
this field that are away from the norm, with concepts that
challenge our perspective and mainstream thoughts as
you never know when a bit of ‘backwater’ research may
become the new hot topic and change the world.
Funding bodies in recent years have often been keen to
see the readily translated consequences from any obesity
research undertaken. Even from a fundamental science
perspective, basic science grant authorities always seem to
require a section or an opening paragraph that has to align
back to health consequences – but without stepping over
the line; often a tricky business to manage. This change
has not only occurred due to economic pressures resulting
in reduced government and charitable basic science
funding, but also due to the global explosion in obesity
and its myriad of metabolic health consequences, all of
which need studying. The demands of modern research
appear different to the mid 90’s when I began in this field;
today we spend increasingly less time at the bench and
more time analysing the data (although this could be
said of every generation). We certainly produce data
much faster than ever before and with a much improved
recognition of other specialities (ranging from mathematical
modelling, Systems Biology, Engineering and digital health-
care), leading to a more interdisciplinary approach to
science. However, for the die-hard bench worker who
should never be forgotten, it is true to say that whilst
many technological advances have occurred, cell culture
and animal studies can still remain relatively slow and
laborious work.
What do you feel are the main advances that have
been made in our research over the recent years in
our quest to understand the causes and links of
metabolism and genetics with obesity – which
advances have particularly interested you?
I should say that genetics has never been a keen strength
of mine. As an undergraduate student my co-worker and I
were tasked to undertake the classic drosophila genetics
experiment to cross white-eyed flies to wild-type red
eyed flies to create an F1 hybrid and so on. An excellent
genetics lesson as it provides a good example with which
you can assess the impact of a trait that depends on a
single gene. With the parental cross all were red eyed,
and in the F1 back cross with white eyed parental-type
there were due to be four colours (red eyes, bright red
eyes, brown and white eyes). However, at some stage
between the parental cross, and F1 back cross, I remember
we managed to produce a one eyed white mutant
drosophila that was not listed at all. My lecturer was
not impressed. I considered at that point that an inability
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if I ever considered embarking on trying to understand
the complexity of human genetics. However, despite this
I feel that monogenic human obesity has shown us the
extreme phenotypes (which are rare when compared to
the more common form of obesity), and these offer a
unique insight into obesity as a whole. Studies in mice
show that these phenotypes highlight that even in these
cases humans are not a simple species.
Polygenic obesity by its nature has been a difficult case
to crack in terms of locating those genes that appear to
raise their head above the significance line. Polygenic
obesity association studies assessing single nucleotide
polymorphisms (SNPs) have noted that many lie within
the first intron of the fat mass– and obesity-associated
gene (FTO) which is strongly associated with adiposity.
In the initial stages before we knew that FTO encoded
for a 2-oxoglutarate (2-OG) Fe2+-dependent dioxygenase,
FTO showed us a revitalising glimpse of how relevant
genetic studies are - despite the large scale heterogenic
complexity of humans. However, it’s clear that under-
standing the functionality aligned with these genes,
challenging though it may be, is vital for continuing
studies. Whilst we know that genes affect our body fat
we also now realize that the naive view that adipose
tissue is just a simple storage organ has certainly gone.
The molecular biology biomarker era and the more
recent epigenetic studies that have been conducted
have certainly given us food for thought on our way to
discovering individual risk profiles. Yet significant new
research programmes have decided we should also
consider more closely what food we eat, and look at
moving towards eating more ‘superfoods’, i.e. using
functional food value as a potential diet related treatment
option to reduce the obesity mediated metabolic risk
for ourselves and offspring. It must seem like a return
to previous times, to understand the benefits that food
in an unprocessed manner may have had on us and our
children, having realised that previous generations were
healthier than current and future ones will be. This
doesn’t mean to say this avenue will be easy, as diets,
gut flora and cellular metabolism thrown together may
present quite a challenge to embark on even in this
time of modern technologies.
What are the new areas of research that are
happening now which you feel are particularly
important?
Focusing on gut flora, I am informed reliably that every-
one has around 1000 bacterial species lining our intestines
at any one time, with 60 % of our dry stool mass being
made up of microbes. Adding to this the fact that at any
one time the people around you at work may have very
different bacterial species diversity or gut flora signatures,makes you wonder how varied all our gut floras may be.
Now for example throw people onto a plane in a confined
space for several hours from different countries, different
homes, and different diets, then you could have up to
10,000 different species being passed around changing the
species diversity and bacterial species proportion in your
gut. Not of course forgetting the prior passengers and the
bacteria they may have left behind. Also spare a thought
for the flight crew who may be receiving and passing
around a lot more than just the drinks.
But why does this matter for obesity research? Well,
although data-wise this research is in its relative infancy,
what our gut flora constitutes of or what our metabolic
gut flora signatures look like, may have quite a profound
effect on our health - both in terms of the capabilities of
the gut flora’s action within the gut, and the impact of
gut derived gram negative bacterial cell wall fragments,
also known as endotoxin, that can pass across the gut
mucosa inducing undesired inflammatory responses and
tissue damage. Furthermore, your gut flora could be
influenced by as little as a single meal which may end up
impacting your health longer term than a more recent
meal. Both the effects of the gut flora in the intestine
and systemically may have implications for metabolic
dysfunction and disease risk. Currently the NIH has 16
out of its 27 centres with programmes funding gut
microbiome work in some form or other and the impact
this has on our health. This is clearly a hot topic area for
the present and future few years and if there was ever a
time to need big data capability, analyzing the human gut
flora surely must be it, as it will be a huge and complicated
task not for the faint hearted or those easily unsettled by
turbulence on the route ahead.
Why do we need a new open access, broad scope
obesity journal – what will BMC obesity be
bringing to the obesity research community?
It is clear that there are a number of high profile diseases
that governments and funders are focussing on, and
rightly so. Interestingly, obesity is often in the background
as a contributing cause to what at times seems like almost
every disease. This being the case, and coupled with
the fact that obesity has a complicated environmental
heterogeneity, means that it remains a very difficult
disease to tackle. Additionally, there is also the creeping
realisation that our obesity doesn’t just affect our own
health but that of our children in the next and subsequent
generations. Even if our future relatives won’t know us
except through a family tree, they may get more from
us than they bargained for. All of this means that the
obesity field has multiple challenges - understanding the
impact of nutrition on our systemic health, its epigenetic
impact, as well as identifying key genetic traits that may
change with our environment and help to further obesity
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diversity of the enduring adipocyte and the new realisation
that adults appear to have brown fat.
Brown fat is important as the brown adipocyte cell is
unlike the white in that it contains an abundance of
mitochondria which dissipate energy readily by generating
heat for the organism through non-shivering thermo-
genesis. It’s clear that nutrition, gut flora, inflammation
and epigenetics are big news for now and the future.
On this basis it is important to have a journal in the
BMC series that can focus exclusively on the rapidly
growing field of obesity, highlighting novel findings
through the online open access platform of the series
and under a journal name that people trust.
Where do you see the obesity research field
heading – what does the future hold and what
work is still to be done?
A common question I am asked when speaking to the
public or keen students on obesity research, or even
friends outside of work, is how far along the road in
obesity research we are. In reply I initially draw upon an
old joke, sometimes sent to friends in their birthday
card. The card depicts a person sitting on the side of the
hill looking over the landscape. The caption underneath
reads, ‘you’re not over the hill yet but you’ve good a
pretty good view’. I would use this analogy to depict
how far we have come in obesity research and how far
we have to go - although some may argue we already
know so much.
Whichever such ideas that we have had already, patting
ourselves on the back for considering how clever we may
have been, reminds me of the story of a US patent office
official who resigned and recommended that the patent
office be closed back in the 1840's as he thought that
everything that could possibly be invented had already
been done! Whilst this has been a funny story passed
around the globe, it appears to be just a myth. There
was no apparent patent officer who resigned and in fact
this story may have been taken out of context from a
report from the Patent Office Commissioner Henry
Ellsworth 1843 report to US Congress, who suggested
that “The advancement of the arts, from year to year
seems to presage the arrival of that period when human
improvement must end.” However, the original myth
seems to perpetuate much more than the commissioner’s
comments. Each generation may now consider that they
have been the brightest and cleverest people to consider
such novel new insights.
This analogy could be easily used in the field of obesity.
Haven’t we discovered the main pieces of evidence to
solve the problem? It is true that we have made significant
advances and to a certain extent one could argue we know
what we should do to reverse obesity through surgicaland weight loss intervention programmes. However, we
still aren’t good at working out individual personal risk
profiles to manage the individual effectively or providing a
long-term cost effective treatment platform considering
the obesity pandemic.
Certainly it seems that future obesity research will
invest heavily into determining the impact of functional
foods on our health, understanding the value of food
produce - their extracts and even individual components.
Particularly as food manufacturers are even keener to
investigate what health benefits their foods may have
on us all. So does obesity research seem to align to that
mythical patent office official who said it was time to
pack up and go as there are no new advances? Absolutely
not, as whilst it is true there has been an upscale in
functional food research we now have much more
sophisticated tools to be able to understand what is
going on and to address whole body metabolism as
well as at the molecular level. Furthermore, if you are
one of those researchers who haven’t noticed the many
new nutritional and health departments or institutes
and staff title changes that have sprung up in this area,
then where have you been?
Obesity research which has led to discoveries of the
links between specific genes such as FTO and obesity,
microRNAs and the change in our understanding of
adipose tissue, amongst others, has not only been highly
interesting but at times shocking. Therefore, as we look
out on the side of the hill considering how far we have
travelled in understanding obesity, are we further up or
lower down the hill? Very few may agree exactly where we
are and how long it might take us to reach the peak or
final destination. In terms of treatment and weight loss
interventions, will we pursue weight loss drugs, as well
as ways of reducing metabolic risk without weight loss via
a functional food or other diet interventions? Will we use
prevention programmes with obesity never becoming
apparent? We know that for those patients with morbid
obesity bariatric surgery is often a way to limit multiple
co-morbidities - although this is not feasible for all. For
most of the population where diet is the key it is apparent
we need ways to necessarily fool our bodies into thinking
or feeling full, whilst considering we may not be dieting!
Part of the solution in our diet is also trying to ensure
that what we eat doesn’t aggregate our tissues into a
pro-inflammatory state, so that perhaps we can live with a
bit more fat without the metabolic complications. This
may arise with diets including functional foods which
may limit systemic inflammation.
The question of what the future holds depends largely
on which obesity strategies we will ultimately deliver
to patients as this changes where we might consider
ourselves to be sitting on the side of that hill and the
view from it, which currently still appears up for grabs.
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and friends, I never say how high up the hill we are or
how long it might take to get to the peak, just that the
outlook is good!
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